DCM
ANIK icon

Delpha Capital Management’s Anika Therapeutics ANIK Stock Holding History

Delpha Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3
Closed – – 186
2017
Q4 		$0 Buy
+3
New +$166 ﹤0.01% 1640

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Delpha Capital Management's ANIK Position: Q1 2018 in Review

Delpha Capital Management sold out of Anika Therapeutics (ANIK) in Q1 2018, closing a stake of 3 shares.

Delpha Capital Management first reported a position in ANIK in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 170 funds tracked by Wall St. Rank hold ANIK as of Q1 2018.

  • Delpha Capital Management reported no remaining Anika Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 3 Anika Therapeutics shares in Q1 2018.
  • Delpha Capital Management first reported a position in Anika Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Anika Therapeutics position peaked at $0 in Q4 2017.
  • 170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.